The U.S. Food and Drug Administration (FDA) is hosting an Ovarian Cancer Endpoints Workshop with presentations by the Society of Gynecologic Oncology, the American Association for Cancer Research and the American Society of Clinical Oncology, along with invited guest speakers, including Deputy Director of Roswell Park, Kunle Odunsi, MD, PhD, FRCOG, FACOG.
The workshop will be held from 8 a.m. to 5 p.m. on Thursday, September 3 at the FDA, White Oak campus Great Room. Dr. Odunsi’s presentation, “How do we study immunotherapy?," is scheduled for 1:30 p.m. to 2:30 p.m. The public is invited to attend via a streaming webcast.
Dr. Odunsi will offer insights into non-cellular immune-based therapeutic strategies. Immunotherapy—using the power of the immune system to fight cancer—is an important scientific research area. This kind of treatment holds the promise of destroying cancer cells more effectively and with fewer side effects than other therapies.
The FDA workshop will provide a forum for discussion of ovarian cancer, from the current state of science to novel clinical trial designs, biomarkers, statistical issues in clinical trials and how to evaluate new classes of agents such as immunotherapies.
Deborah Pettibone, Public Information Specialist